August 23, 2021 -- Pfizer plans to acquire immuno-oncology drug developer Trillium Therapeutics for $2.26 billion in a deal that will expand Pfizer's portfolio to include immunotherapeutics for blood diseases.
Trillium's biologics are designed to help the immune system of patients identify and destroy cancer cells, Pfizer said. Its two lead candidates include the signal-regulatory protein alpha fragment crystallizable region (SIRPα-Fc) fusion proteins TTI-622 and TTI-621, which block the key immune checkpoint SIRPα-CD47 axis. The molecules are currently in phase IB/II development.
The move comes almost a year after Pfizer invested $25 million in Trillium as part of its Pfizer Breakthrough Growth Initiative, which offers scientific research funding and access to Pfizer's experts, it said.
Already have an account? Sign in Here
To access all ScienceBoard content create a free account now: